Skip to main content Accessibility help
Hostname: page-component-6c8bd87754-fppf4 Total loading time: 0.454 Render date: 2022-01-19T21:03:54.474Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

3 - Hormones in cancer

Published online by Cambridge University Press:  05 November 2015

Jacinta Abraham
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
John Staffurth
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Louise Hanna
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access



Hormonal therapies are some of the oldest active systemic anti-cancer therapies in use today. In 1896, Beatson demonstrated that surgical oophorectomy resulted in tumour regression in some premenopausal women with metastatic breast cancer, and, by doing so, he was the first to identify a link between ovarian function and breast cancer (Beatson, 1896).

Substantial evidence now exists that hormones play a key role in both the cause and the outcome of several cancers. Although this is most clearly seen in breast and prostate cancer, other cancers that may exhibit hormone dependence include endometrial, ovarian and testicular cancers.

Hormones are classified into two groups:

  1. • non-steroidal hormones including peptides, polypeptides or derivatives of amino acids, generally acting via cell-membrane-localised receptors which trigger second messengers within the cytoplasm; and

  2. • steroidal hormones, such as oestrogens, androgens and progestins, bind to intracellular receptors to mediate their action.

This chapter will focus primarily on steroidal hormones that are of particular importance in breast and prostate cancer: oestrogens, progestins and androgens. It should be read in conjunction with the relevant site-specific chapters (Chapters 19 and 22). This chapter provides some background knowledge of the production and functioning of hormones and their receptors, which will help in the understanding of commonly used therapies. The aetiology of hormone-related cancers is discussed in the relevant site-specific chapters.

Steroidal hormones have the potential to activate oncogenes or inactivate tumour-suppressor genes, producing a sequence of changes within the cell that ultimately lead to cancer. The continued growth of the cancer often depends on continuing hormone stimulation and so removing the hormonal stimulus causes the cancer to regress. Anti-cancer hormone therapies work in a number of different ways – by affecting hormone synthesis, metabolism or action, or by altering hormone receptor expression within the cell.

A summary of the major historical landmarks in anti-cancer hormonal therapy since Beatson's observation in 1896 is listed here.

Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Anonymous, . (1997). Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br. J. Urol., 79, 235–246.Google Scholar
Armstrong, J. G., Gillham, C. M. and Dunne, M. T. (2011). A randomized trial (Irish Clinical Oncology Research Group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 81, 35–45.CrossRefGoogle ScholarPubMed
Beatson, G. T. (1896). On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet, ii, 104–107.Google Scholar
Bliss, J., Kilburn, L. S., Coleman, R. E., et al. (2012). Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J. Clin. Oncol., 30, 709–717.CrossRefGoogle ScholarPubMed
Boccardo, F., Rubagotti, A., Battaglia, M., et al. (2005). Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J. Clin. Oncol., 23, 808–815.CrossRefGoogle ScholarPubMed
Bolla, M., Gonzalez, D., Warde, P., et al. (1997). Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med., 337, 295–300.CrossRefGoogle ScholarPubMed
Bolla, M., Collette, L., Blank, L., et al. (2002). Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet, 360, 103–106.CrossRefGoogle ScholarPubMed
Bolla, M., de Reijke, T. M., Van Tienhoven, G., et al. (2009). Duration of androgen suppression in the treatment of prostate cancerN. Engl. J. Med., 360, 2516–2527.CrossRefGoogle ScholarPubMed
Crook, J. M., Ludgate, C., Malone, S., et al. (2009). Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 73, 327–333.CrossRefGoogle ScholarPubMed
Crook, J. M., O'Callaghan, C. J., Duncan, G, et al. (2012). Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med., 367, 895–903.CrossRefGoogle ScholarPubMed
Cuzick, J., Sestak, I, Baum, M., et al. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10 year analysis of the ATAC trial. Lancet Oncol., 11, 1135–1141.CrossRefGoogle ScholarPubMed
Cuzick, J., Sestak, I. and Forbes, J. F. (2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, 383, 1041–1048.CrossRefGoogle ScholarPubMed
D'Amico, A. V., Kantoff, P., Loffredo, M., et al. (2006). Predictors of mortality after prostate-specific antigen failure. Int. J. Radiat. Oncol. Biol. Phys., 65, 656–660.Google ScholarPubMed
D'Amico, A. V., Denham, J. W., Crook, J. M., et al. (2007). Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol., 25, 2420–2425.CrossRefGoogle ScholarPubMed
D'Amico, A. V., Chen, M-H., Renshaw, A. A., et al. (2008). Androgen suppression and radiation vs radiation alone for prostate cancer. J. Am. Med. Ass., 299, 289–295.Google ScholarPubMed
Davis, C., Pan, H., Godwin, J., et al. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet, 381, 805–816.Google Scholar
Denham, J. W., Steigler, A. and Lamb, D. S. (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol., 12, 451–459.CrossRefGoogle Scholar
Dowsett, M., Cuzick, J., Wale, C., et al. (2005). Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol., 23, 7512–7517.CrossRefGoogle ScholarPubMed
EBCTCG. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687–1717.
EBCTCG. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378 , 771–784.
Fellows, G. J., Clark, P. B., Beynon, L. L., et al. (1992). Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party – Subgroup on Prostatic Cancer. Br. J. Urol., 70, 304–309.CrossRefGoogle ScholarPubMed
Fisher, B., Costantino, J., Redmond, C., et al. (1989). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have oestrogen-receptor-positive tumors. N. Engl. J. Med., 320, 479–484.Google Scholar
Fizazi, K., Scher, H., Molina, A., et al. (2012). Abiraterone acetate for the treatment of metastatic castrate-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol., 13, 983–992.CrossRefGoogle Scholar
Gray, R. G., Rea, D., Handley, K., et al. (2013). aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. J Clin Oncol., 31 (Suppl.), abstr. 5.CrossRefGoogle Scholar
Horwitz, E. M., Bae, K., Hanks, G. E., et al. (2008). Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol., 26, 2497–2504.CrossRefGoogle ScholarPubMed
Hopp, T. A., Weiss, H. L., Hilsenbeck, S. G., et al. (2004). Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival states. Clin. Cancer Res., 10, 2751–2760.CrossRefGoogle Scholar
Howell, A., Cuzick, J., Baum, M., et al. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet, 365, 60–62.Google ScholarPubMed
Huggins, C. and Bergenstal, D. M. (1952). Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res., 12, 134–141.Google ScholarPubMed
Huggins, C. and Hodges, C. V. (1941). Studies on prostate cancer. The effects of castration, of oestrogen and of androgen injection on serum phosphatases in carcinoma of the prostate. Cancer Res., 1, 293–297.Google Scholar
Hussain, S. A., Weston, R., Stephenson, R. N., et al. (2003). Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int., 92, 690–694.CrossRefGoogle ScholarPubMed
Hussain, S. A., Tangen, C. M., Berry, D. L., et al. (2013). Intermittent versus continuous androgen deprivation therapy in prostate cancer. N. Engl. J. Med., 368, 1314–1325.CrossRefGoogle ScholarPubMed
Iversen, P., Tyrrell, C. J., Kaisary, A. V., et al. (2000). Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J. Urol., 164, 1579–1582.CrossRefGoogle ScholarPubMed
Jin, H., Tu, D., Zhao, N.,et al. (2012). Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover. J. Clin. Oncol., 30, 718–721.CrossRefGoogle ScholarPubMed
Joerger, M. and Thurlimann, B. (2009). Update of the BIG 1–98 trial: where do we stand?Breast, 18, 78–82.CrossRefGoogle ScholarPubMed
Jones, C. U., Hunt, D., McGowan, D. G., et al. (2011). Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med., 365, 107–118.CrossRefGoogle ScholarPubMed
Laverdiere, J., Nabid, A., De Bedoya, L. D., et al. (2004). The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2–T3 prostate cancer. J. Urol., 171, 1137–1140.CrossRefGoogle Scholar
McLeod, D. G., Iversen, P., See, W. A., et al. (2006). Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int., 97, 247–254.CrossRefGoogle ScholarPubMed
Messing, E. M., Manola, J., Yao, J., et al. (2006). Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol., 7, 472–479.CrossRefGoogle ScholarPubMed
Milano, A., Dal Lago, L., Sotiriou, C., et al. (2006). What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur. J. Cancer, 42, 2692–2705.CrossRefGoogle ScholarPubMed
Miller, W. R., Anderson, T. J., Dixon, J. M., et al. (2006). Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br. J. Cancer, 94, 1333–1338.CrossRefGoogle Scholar
Noble, R. L. (1980). Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res., 40, 3547–3550.Google ScholarPubMed
Perdona, S., Autorino, R., De Placido, S., et al. (2005). Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol., 6, 295–300.CrossRefGoogle ScholarPubMed
Pilepich, M. V., Winter, K., Lawton, C. A., et al. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85–31. Int. J. Radiat. Oncol. Biol. Phys., 61, 1285–1290.CrossRefGoogle ScholarPubMed
Roach, M. 3rd, Bae, K. and Speight, J. (2008). Short-term neoadjuvant androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. Biol. Phys., 26, 585–591.Google ScholarPubMed
Rodrigues, N. A., Chen, M. H., Catalona, W. J., et al. (2006). Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer, 107, 514–520.CrossRefGoogle ScholarPubMed
Ryan, C. J., Smith, M., de Bono, J. S., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med., 368, 138–148.CrossRefGoogle ScholarPubMed
Scher, H., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., 367, 1–11.CrossRefGoogle ScholarPubMed
Schmitt, B., Bennett, C., Seidenfeld, J., et al. (2000). Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst. Rev., 2, CD001526.Google Scholar
See, W. A. and Tyrrell, C. J. (2006). The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J. Cancer Res. Clin. Oncol., 132 (Suppl. 13), 7–16.CrossRefGoogle ScholarPubMed
Shahinian, V. B., Kuo, Y. F., Freeman, J. L., et al. (2005). Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med., 352, 154–164.CrossRefGoogle ScholarPubMed
Smith, I. E., Dowsett, M., Yap, Y. S., et al. (2006). Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J. Clin. Oncol., 24, 2444–2447.CrossRefGoogle ScholarPubMed
Smith, M. R., Eastham, J., Gleason, D. M., et al. (2003). Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol., 169, 2008–2012.CrossRefGoogle ScholarPubMed
Tyrrell, C. J., Payne, H., See, W. A., et al. (2005). Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother. Oncol., 76, 4–10.CrossRefGoogle ScholarPubMed
Vogel, V. G. (2009). The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert. Rev. Anticancer Ther., 9, 51–60. Erratum in Expert. Rev. Anticancer Ther., 9, 388.CrossRefGoogle ScholarPubMed
Wirth, M. P., See, W. A., McLeod, D. G., et al. (2004). Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J. Urol., 172(5 Pt. 1), 1865–1870.CrossRefGoogle ScholarPubMed
Zelefsky, M. J. and Harrison, A. (1997). Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology, 49 (Suppl. 3A), 38–45.CrossRefGoogle Scholar
Zondek, B. (1940). Effect of prolonged administration of oestrogen on uterus and anterior pituitary of human beings. J. Am. Med. Ass., 114, 1850–1854.CrossRefGoogle Scholar

Send book to Kindle

To send this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats